Biotech selling Filspari, an oral drug for IgA nephropathy, a rare progressive kidney disease.
Biotech selling Filspari, an oral drug for IgA nephropathy, a rare progressive kidney disease.
Sells Filspari through specialty pharmacies on prescriptions written by kidney specialists, and relies on it for growth while older rare-disease drugs such as Thiola, for the kidney-stone disorder cystinuria, give a smaller, steadier base. Formerly Retrophin, it moved Filspari from accelerated to full US approval for IgA nephropathy in 2024.
Moat: narrow (IP / patents, regulatory licence). One of few approved oral therapies specifically for IgA nephropathy, with orphan-drug protections.
Headquarters: San Diego, California, United States · Founded: 2003 · Employees: 497
Size Travere Therapeutics (TVTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.82B, the 1201st largest of 3,085 United States companies the cockpit tracks. Shares closed at $50.24 on 18 Nov 2026.
Performance Over six months the shares gained 15.5%, against +10.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 49.4% over the last twelve months (peer median +11.3%); the operating margin is -3.1% (peer median 19.4%).
Valuation It trades at 17.1× forward earnings against a peer median of 25.8× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 19.7 points below its cost of capital (10.1% WACC).
Credit Travere Therapeutics has 1 bond outstanding ($525M).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $651M | $491M | $233M | $145M | $109M |
| Revenue growth | — | +110% | +61% | +33% | — |
| Gross profit | $589M | $420M | $182M | $95.3M | $84.3M |
| EBITDA | $32.4M | -$2.08M | -$213M | -$338M | -$299M |
| Net income | -$154M | -$50.3M | -$322M | -$337M | -$278M |
| Free cash flow | $177M | $37.8M | -$237M | -$281M | -$186M |
| Capital expenditure | $90.9M | $58.2M | $36.2M | $42.3M | $28.6M |
| Total debt | $616M | $329M | $402M | $405M | $407M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Travere Therapeutics TVTX | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| Vera Therapeutics VERA | $1.85B | -26% | n/a | -4,160% | n/a | n/a |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 28.5× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TVTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.9% | +0.2% | 9th lowest of 21 |
| 6-month return | +15.5% | +10.4% | 5th highest of 21 |
| Distance from 52-week high | -26.9% | -27.6% | 11th highest of 21 |
| Revenue growth (TTM) | +49.4% | +11.3% | 2nd highest of 19 |
| Operating margin | -3.1% | 19.4% | 2nd lowest of 19 |
| Forward P/E | 17.1× | 25.8× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 17.3% | 3.4% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +19.9% | +10.9% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | -2.5 pp | -6.3 pp | 7th most demanding of 17 |
| ROIC minus cost of capital | -19.7 pp | +5.1 pp | 3rd lowest of 17 |
| Net debt / EBITDA | 4.5× | -0.8× | most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
Travere Therapeutics has 1 bond outstanding with $525M face value.